The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
Daniel A R HeiseyTimothy L LochmannKonstantinos V FlorosColin M CoonKrista M PowellSheeba JacobMarissa L CalbertManinderjit S GhotraGiovanna T SteinYuki Kato MavesSteven Christopher SmithCyril H BenesJoel D LeversonAndrew J SouersSosipatros A BoikosAnthony C FaberPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
These data reveal BCL-2 and BCL-XL act together to drive olaparib resistance in Ewing sarcoma and reveal a novel, rational combination therapy that may be put forward for clinical trial testing.